Syncytia formation by SARS-CoV-2 infected cells
Abstract Severe cases of COVID-19 are associated with extensive lung damage and the presence of infected multinucleated syncytial pneumocytes. The viral and cellular mechanisms regulating the formation of these syncytia are not well understood. Here, we show that SARS-CoV-2 infected cells express the viral Spike protein (S) at their surface and fuse with ACE2-positive neighbouring cells. Expression of S without any other viral proteins triggers syncytia formation. Type-I interferon (IFN)-induced transmembrane proteins (IFITMs), a family of restriction factors that block the entry of many viruses, inhibit S-mediated fusion, with IFITM1 being more active than IFITM2 and IFITM3. On the contrary, the TMPRSS2 serine protease, which is known to enhance infectivity of cell-free virions, processes both S and ACE2 and increases syncytia formation by accelerating the fusion process. TMPRSS2 thwarts the antiviral effect of IFITMs. Our results show that the pathological effects of SARS-CoV-2 are modulated by cellular proteins that either inhibit or facilitate syncytia formation.One Sentence Summary Syncytia produced by SARS-CoV-2 infected cells and regulation of their formation by IFITMs and TMPRSS2..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 25. März Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Buchrieser, Julian [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.07.14.202028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018361552 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018361552 | ||
| 003 | DE-627 | ||
| 005 | 20230429082129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200721s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.14.202028 |2 doi | |
| 035 | |a (DE-627)XBI018361552 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.07.14.202028 | ||
| 035 | |a (biorXiv)10.1101/2020.07.14.202028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Buchrieser, Julian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Syncytia formation by SARS-CoV-2 infected cells |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Severe cases of COVID-19 are associated with extensive lung damage and the presence of infected multinucleated syncytial pneumocytes. The viral and cellular mechanisms regulating the formation of these syncytia are not well understood. Here, we show that SARS-CoV-2 infected cells express the viral Spike protein (S) at their surface and fuse with ACE2-positive neighbouring cells. Expression of S without any other viral proteins triggers syncytia formation. Type-I interferon (IFN)-induced transmembrane proteins (IFITMs), a family of restriction factors that block the entry of many viruses, inhibit S-mediated fusion, with IFITM1 being more active than IFITM2 and IFITM3. On the contrary, the TMPRSS2 serine protease, which is known to enhance infectivity of cell-free virions, processes both S and ACE2 and increases syncytia formation by accelerating the fusion process. TMPRSS2 thwarts the antiviral effect of IFITMs. Our results show that the pathological effects of SARS-CoV-2 are modulated by cellular proteins that either inhibit or facilitate syncytia formation.One Sentence Summary Syncytia produced by SARS-CoV-2 infected cells and regulation of their formation by IFITMs and TMPRSS2. | ||
| 700 | 1 | |a Dufloo, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Hubert, Mathieu |e verfasserin |4 aut | |
| 700 | 1 | |a Monel, Blandine |e verfasserin |4 aut | |
| 700 | 1 | |a Planas, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Rajah, Maaran Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Planchais, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Porrot, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Guivel-Benhassine, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Van der Werf, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Casartelli, Nicoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Mouquet, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Bruel, Timothée |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Olivier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 25. März |
| 773 | 1 | 8 | |g year:2021 |g day:25 |g month:03 |
| 856 | 4 | 0 | |u https://doi.org/10.15252/embj.2020106267 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.14.202028 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 25 |c 03 | ||
| 953 | |2 045F |a 570 | ||